Announced Wed, 22 Apr · 09:13 IST
Lupin launches diabetes drug in US after FDA approval
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.5%1-day move
₹2312.90
prior close
₹2304.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6-0.9-0.5-0.4+1.5-0.6+0.3-0.4-0.4+1.6-2.6-1.8+1.3+4.0
Up moveDown movePending
AI summary
Lupin has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the US after receiving FDA approval for its ANDA. The product is a generic equivalent of AstraZeneca's Xigduo XR, available in 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg strengths, used for diabetes treatment. This expands Lupin's anti-diabetic portfolio in the US market.
Likely market impact
Adds a new revenue stream in the lucrative US generics market; supports US business growth but competitive pricing pressure on margins is likely.